Multicenter analysis shows overall survival of 77% and event-free survival of 47% in intermediate-risk AML patients, indicating effective risk stratification strategies.
Key Points
The overall survival rate for intermediate-risk patients reaches 77%, showing promising treatment outcomes.
Among patients with biallelic CEBPA mutations, a favorable prognosis is noted, highlighting genetic factors in treatment effectiveness.
The study utilized data from 525 patients treated under the AML-MRD-2018 protocol across 54 hospitals in Russia.
This research supports the necessity for ongoing improvements in treatment regimens for acute myeloid leukemia.